Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression

Nikkhoo, Afshin; Rostami, Narges; Farhadi, Sareh; Esmaily, Maryam; Ardebili, Sadaf Moghadaszadeh; Atyabi, Fatemeh; Baghaei, Masoumeh; Haghnavaz, Navideh; Yousefi, Mehdi; Aliparasti, Mohammad Reza; Ghalamfarsa, Ghasem; Mohammadi, Hamed; Sojoodi, Mozhdeh; Jadidi‐Niaragh, Farhad

doi:10.1016/j.ijpharm.2020.119236

Cited by 67 publications

(23 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yu et al demonstrated that CNPs-delivered CXCR4 siRNA reduced the CXCR4 expression and sensitizes breast cancer cells to cisplatin [ 17 ]. Nikkhoo et al confirmed that carboxymethyl dextran-conjugated trimethyl chitosan (TMC-CMD) nanoparticles loaded with NIK/STAT3-specific siRNA and BV6 to synergistically induce apoptosis in the breast, colorectal, and melanoma cancer cell lines [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

NEAT1 siRNA Packed with Chitosan Nanoparticles Regulates the Development of Colon Cancer Cells via lncRNA NEAT1/miR-377-3p Axis

Deng

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

This study was for verifying that transfecting colon cancer cells (CCCs) with lncRNA NEAT1 packed with siRNA chitosan nanoparticles (CNPs) can suppress lncRNA NEAT1 and biological behaviors of the cells. siRNA targeting lncRNA NEAT1 expression vector was constructed and then transfected into CCCs after being packed with CNPs. Subsequently, the impact of the transfection on biological behaviors of the cells was evaluated. As a result, with high expression in CCCs, NEAT1 was negatively bound up with miR-377-3p in cases with colon cancer (CC), and dual luciferase reporter assay confirmed the potential binding region. Additionally, after downregulating NEAT1 in CCCs, transfection of NEAT1 siRNA packed with CNPs brought a great inhibition on cell proliferation and a promotion on apoptosis, and inhibiting miR-377-3p was able to offset the role of silencing NEAT1 in CCCs. Therefore, in our opinion, NEAT1 siRNA packed with CNPs can hinder the growth and metastasis of CCCs by knocking down NEAT1 in CC, and its mechanism may be achieved by targeting miR-377-3p, which offers a novel direction for treating CC.

show abstract

Section: Introductionmentioning

confidence: 99%

NEAT1 siRNA Packed with Chitosan Nanoparticles Regulates the Development of Colon Cancer Cells via lncRNA NEAT1/miR-377-3p Axis

Deng

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Trizol reagent (Takara Biotechnology, China) was employed to extract the total RNA and the synthesis of cDNA was conducted using the Prime Script™ RT reagent kit in accordance with the manufacturer's instruction. The relative mRNA expression analysis of Sox2 gene was carried out via the 2- ΔΔCT method [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma

Xia

Tang

Chen

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

RNA interference (RNAi) is one of the most promising methods for the treatment of malignant tumors. However, developing an efficient biocompatible delivery vector for small interfering RNA (siRNA) remains a challenging issue. This study aimed to prepare a non-viral tumor-targeted carrier, named RGDfC-modified functionalized selenium nanoparticles (RGDfC-SeNPs). RGDfC-SeNPs were used to selectively deliver siSox2 to HepG2 liver cancer cells and tissues for the treatment of hepatocellular carcinoma (HCC). In the current study, RGDfC-SeNPs were successfully synthesized and characterized. It was shown that RGDfC-SeNPs could effectively load siSox2 to prepare an antitumor prodrug RGDfC-Se@siSox2. RGDfC-Se@siSox2 exhibited selective uptake in HepG2 liver cancer cells and LO2 normal liver cells, indicating RGDfC-SeNPs could effectively deliver siSox2 to HepG2 liver cancer cells. RGDfC-Se@siSox2 entered HepG2 cells via clathrin-mediated endocytosis by firstly encircling the cytoplasm and then releasing siSox2 in the lysosomes. RGDfC-Se@siSox2 could effectively silence Sox2 and inhibit the proliferation, migration and invasion of HepG2 cells. RGDfC-Se@siSox2 induced HepG2 cells apoptosis most likely via overproduction of reactive oxygen species and disruption of the mitochondrial membrane potentials. Most importantly, RGDfC-Se@siSox2 significantly inhibited the tumor growth in HepG2 tumor-bearing mice without obvious toxic side effects. These studies indicated that RGDfC-SeNPs may be an ideal gene carrier for delivering siSox2 to HepG2 cells and that RGDfC-Se@siSox2 may be a novel and highly specific gene-targeted prodrug therapy for HCC.

show abstract

“…This combination has the potential to induce effective apoptosis in tumor cells. Nikhoo et al [223] used carboxymethyl dextran-conjugated trimethyl chitosan (CMD/TMC) NPs loaded with NIK/STAT3-specific siRNA and BV6 to synergistically induce apoptosis in the breast, colorectal, and melanoma cancer cell lines. Their results showed that in addition to enhanced pro-apoptotic effects, this combined therapy reduced proliferation, cell migration, colony formation, and an-giogenesis, along with the expression of factors including IL-10 and HIF in the tumor cells.…”

Section: Gene Deliverymentioning

confidence: 99%

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Mikušová

Mikuš

2021

IJMS

295

120

View full text Add to dashboard Cite

Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug carriers because of some intrinsic beneficial properties including biocompatibility, biodegradability, non-toxicity, bioactivity, easy preparation, and targeting specificity. Drug transport and release from CS-based particulate systems depend on the extent of cross-linking, morphology, size, and density of the particulate system, as well as physicochemical properties of the drug. All these aspects have to be considered when developing new CS-based NPs as potential drug delivery systems. This comprehensive review is summarizing and discussing recent advances in CS-based NPs being developed and examined for drug delivery. From this point of view, an enhancement of CS properties by its modification is presented. An enhancement in drug delivery by CS NPs is discussed in detail focusing on (i) a brief summarization of basic characteristics of CS NPs, (ii) a categorization of preparation procedures used for CS NPs involving also recent improvements in production schemes of conventional as well as novel CS NPs, (iii) a categorization and evaluation of CS-based-nanocomposites involving their production schemes with organic polymers and inorganic material, and (iv) very recent implementations of CS NPs and nanocomposites in drug delivery.

show abstract

Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression

Cited by 67 publications

References 46 publications

NEAT1 siRNA Packed with Chitosan Nanoparticles Regulates the Development of Colon Cancer Cells via lncRNA NEAT1/miR-377-3p Axis

NEAT1 siRNA Packed with Chitosan Nanoparticles Regulates the Development of Colon Cancer Cells via lncRNA NEAT1/miR-377-3p Axis

Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Contact Info

Product

Resources

About